Is this SDS the latest revision?

This Safety Data Sheet was issued by Celgene Corporation on 21 May 2019 under OSHA. ISDSS syncs its database regularly to keep documents current.

Do I need to register to download this SDS?

Yes, a free ISDSS account is required to download the PDF. Registration takes under two minutes and gives you access to over 1.5 million Safety Data Sheets. Once registered, you can also save documents to your personal library for quick access.

Who is responsible for providing an SDS?

The manufacturer, importer or supplier that places the substance on the market is responsible for providing a current Safety Data Sheet to downstream users, free of charge.

Can I use this SDS as my COSHH risk assessment?

No. An SDS provides the hazard information you need, but a COSHH assessment must consider how the substance is actually used in your workplace. The matching Chemical Risk Assessment (CRA) on this page is a starting point you should adapt to your own tasks and controls.

Safety Data SheetChemical Risk Assessment

Revlimid (Lenalidomide) Capsules

by Celgene Corporation

SDS · PDF, approx. 220 KB CRA · PDF, approx. 180 KB

Revlimid (Lenalidomide) Capsules is supplied by Celgene Corporation. This page provides both the Safety Data Sheet (SDS) and the Chemical Risk Assessment (CRA) for this substance, under OSHA regulations for UK workplace use under COSHH. The full SDS and CRA documents are available to download above.

This SDS was last revised on 21 May 2019. The matching CRA is updated in line with SDS revisions. Workplaces handling this substance should retain a current SDS and risk assessment for the duration of use.

Language: English
Regulation: OSHA
Revision Date: 21 May 2019
Signal Word: DANGER
Product Code: —
CAS Number: 9004-34-6,191732-72-6,557-04-0

Switch between the Safety Data Sheet and the Chemical Risk Assessment for this substance.